Good News for Lupin

Good News for LupinLupin Limited's US subsidiary, Lupin Pharmaceuticals, Inc has been able to receive the final authorization for the company's Abbreviated New Drug Application for its lamotrigine tablets, 25 mg, 100 mg, 150 mg and 200 mg strengths, from the US Food and Drug Administration.

Lupin's Lamotrigene is the AB-rated generic correspondent of GlaxoSmithKline's Lamictal tablets that is asserted to be given for the maintenance treatment of bipolar I disorder and is also indicated as adjunctive treatment for definite seizure types.

Lamictal tablets had yearly sales of just about US$ 452 million for the twelve months that ended in March 2010.